Christopher Michael Palmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christopher Michael Palmer has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Javier Gilbert-Jaramillo
Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts, USA
3 shared publications - Aaron John MacDonald
McLean Hospital, Belmont, MA, United States
2 shared publications - Oluwarotimi O. Folorunso
Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts, USA
2 shared publications - Zoltán Sarnyai
Laboratory of Psychiatric Neurosciences, Australian Institute of Tropical Health and Medicine, James Cook University, Australia
2 shared publications - Aaron J MacDonald
Division of Depression & Anxiety Disorders, McLean Hospital, Belmont, MA, 02478, USA
1 shared publication Aava Bushra Jahan
Harvard Medical School/Massachusetts General Hospital, Boston, USA
1 shared publication
Latest Publications
- Open Access
Acute Ethanol Exposure Induces Stage-Specific Bioenergetic, Mitochondrial and Neurodevelopmental Transcriptional Remodeling in Human Forebrain Progenitors
Prenatal alcohol exposure (PAE) is associated with long-term neurodevelopmental risk, yet how neuronal progenitor metabolism responds to alcohol across developmental stages remains unclear. Here, we integrated brain-isoform–focused analysis of public datasets with targeted transcriptional, translational, and functional mitochondrial assessments in human iPSC-derived cortical progenitor models representing distinct bioenergetic states. Re-analysis of prior PAE studies revealed broad metabolic gene downregulation in embryonic systems, whereas neurodevelopmental models showed limited and non-coherent transcriptional signatures. In vitro , acute ethanol exposure (AEE) induced stage-dependent transcriptional remodeling in iPSC-derived neuronal progenitor cells. Early progenitors exhibited selective upregulation of mitochondrial-associated transcripts alongside increased neuronal lineage markers. In contrast, late progenitors showed broader increases in glycolytic, lipid, and mitochondrial gene expression. Despite these transcriptional changes, mitochondrial ATP production and mitochondrial protein abundance remained unchanged in both models with altered dynamics being restricted to late progenitors. These findings indicate that ethanol exposure is associated with developmental stage–dependent neuronal remodeling of bioenergetic genes. Measurements of mitochondrial-neural frameworks after AEE showed no major alterations in either model. Overall, our results reveal a dissociation between transcriptional, translational, and functional bioenergetic outputs in models of early human neurodevelopment and highlight that transcriptional alterations of mitochondria and cellular bioenergetics under AEE should be interpreted in the context of developmental stage rather than in isolation as evidence of energetic dysfunction.
Open AccessAcute Ethanol Exposure Induces Stage-Specific Bioenergetic, Mitochondrial and Neurodevelopmental Transcriptional Remodeling in Human Forebrain Progenitors
Prenatal alcohol exposure (PAE) is associated with long-term neurodevelopmental risk, yet how neuronal progenitor metabolism responds to alcohol across developmental stages remains unclear. Here, we integrated brain-isoform–focused analysis of public datasets with targeted transcriptional, translational, and functional mitochondrial assessments in human iPSC-derived cortical progenitor models representing distinct bioenergetic states. Re-analysis of prior PAE studies revealed broad metabolic gene downregulation in embryonic systems, whereas neurodevelopmental models showed limited and non-coherent transcriptional signatures. In vitro , acute ethanol exposure (AEE) induced stage-dependent transcriptional remodeling in iPSC-derived neuronal progenitor cells. Early progenitors exhibited selective upregulation of mitochondrial-associated transcripts alongside increased neuronal lineage markers. In contrast, late progenitors showed broader increases in glycolytic, lipid, and mitochondrial gene expression. Despite these transcriptional changes, mitochondrial ATP production and mitochondrial protein abundance remained unchanged in both models with altered dynamics being restricted to late progenitors. These findings indicate that ethanol exposure is associated with developmental stage–dependent neuronal remodeling of bioenergetic genes. Measurements of mitochondrial-neural frameworks after AEE showed no major alterations in either model. Overall, our results reveal a dissociation between transcriptional, translational, and functional bioenergetic outputs in models of early human neurodevelopment and highlight that transcriptional alterations of mitochondria and cellular bioenergetics under AEE should be interpreted in the context of developmental stage rather than in isolation as evidence of energetic dysfunction.
- Open Access
Developmental Bioenergetic Reprogramming and Glycolytic Shift in Schizophrenia Vulnerability
Schizophrenia (SZ) arises from complex gene-environment interactions, yet how early insults shape later circuit vulnerability remains unclear. Here, we investigated whether bioenergetic states represent a convergent disease signature across genetic and environmental risk factors. We analyzed transcriptional profiles across neocortical development in murine models of maternal immune activation (polyIC MIA), and serine racemase deletion (Srr⁻/⁻), extending these analyses to juvenile stages in Srr-/- and interneuron-specific NMDA receptor deletion (Nkx2.1:Grin1fl/fl), highlighting cell-type-specific metabolic vulnerability across developmental stages. In MIA, early gestation (E12.5) revealed a transient bioenergetic shift likely driven by microglial and radial glial populations, suggesting metabolic priming rather than canonical inflammatory signaling. By late gestation (E17.5), MIA induced coordinated dysregulation of neuronal glycolytic isoforms alongside mitochondrial and lipid-associated metabolic pathways, suggesting coordinated metabolic remodeling involving lipid-linked processes. In contrast, Srr⁻/⁻ mice showed minimal glycolytic alterations at E17.5, indicating that isolated genetic perturbation is insufficient to recapitulate this fetal metabolic state. However, at juvenile stages, region-specific bioenergetic adaptations emerged. Srr⁻/⁻ mice exhibited global cortical increases in glycolytic gene expression, with hippocampal changes potentially enriched in neuronal populations. Conversely, Nkx2.1:Grin1fl/flinterneurons showed increased glycolytic and TCA cycle transcription in the hippocampus but opposing patterns in the medial prefrontal cortex. Together, these findings identify increased glycolytic activity, potentially linked to lactate metabolism, as a partially convergent developmental mechanism bridging prenatal perturbations and later circuit dysfunction in SZ, and suggest that downstream glycolysis-linked pathways may contribute to phenotypic heterogeneity. Graphical Abstract
Open AccessDevelopmental Bioenergetic Reprogramming and Glycolytic Shift in Schizophrenia Vulnerability
Schizophrenia (SZ) arises from complex gene-environment interactions, yet how early insults shape later circuit vulnerability remains unclear. Here, we investigated whether bioenergetic states represent a convergent disease signature across genetic and environmental risk factors. We analyzed transcriptional profiles across neocortical development in murine models of maternal immune activation (polyIC MIA), and serine racemase deletion (Srr⁻/⁻), extending these analyses to juvenile stages in Srr-/- and interneuron-specific NMDA receptor deletion (Nkx2.1:Grin1fl/fl), highlighting cell-type-specific metabolic vulnerability across developmental stages. In MIA, early gestation (E12.5) revealed a transient bioenergetic shift likely driven by microglial and radial glial populations, suggesting metabolic priming rather than canonical inflammatory signaling. By late gestation (E17.5), MIA induced coordinated dysregulation of neuronal glycolytic isoforms alongside mitochondrial and lipid-associated metabolic pathways, suggesting coordinated metabolic remodeling involving lipid-linked processes. In contrast, Srr⁻/⁻ mice showed minimal glycolytic alterations at E17.5, indicating that isolated genetic perturbation is insufficient to recapitulate this fetal metabolic state. However, at juvenile stages, region-specific bioenergetic adaptations emerged. Srr⁻/⁻ mice exhibited global cortical increases in glycolytic gene expression, with hippocampal changes potentially enriched in neuronal populations. Conversely, Nkx2.1:Grin1fl/flinterneurons showed increased glycolytic and TCA cycle transcription in the hippocampus but opposing patterns in the medial prefrontal cortex. Together, these findings identify increased glycolytic activity, potentially linked to lactate metabolism, as a partially convergent developmental mechanism bridging prenatal perturbations and later circuit dysfunction in SZ, and suggest that downstream glycolysis-linked pathways may contribute to phenotypic heterogeneity. Graphical Abstract
- Open Access
- 8 April 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1815787
Emergence of hypomania and mania following initiation of a ketogenic diet: case series
The ketogenic diet is a century-old, evidence-based treatment for drug-refractory epilepsy, and is now also utilized as an evidence-based treatment for obesity and type 2 diabetes. Emerging research suggests that it may play a role in the treatment of serious mental illness, including treatment-resistant depression, bipolar disorder, and schizophrenia. As with any powerful therapeutic intervention, there can sometimes be side effects. This case series of 9 participants describes 8 who experienced hypomania and 1 who experienced mania within 2 months of starting a ketogenic diet. Of note, 7 of the participants did not have a prior history of a bipolar-spectrum disorder. None of the participants required hospitalization or the addition of mood-stabilizing medications as a result of these mood episodes. Nonetheless, individuals and clinicians should be aware of this risk when using the ketogenic diet, monitor for symptoms of hypomania and mania, and use appropriate strategies to manage symptoms if they emerge. These findings also raise intriguing questions and offer possible insights into the phenomenology of hypomania and mania.
- 8 April 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1815787
Open AccessEmergence of hypomania and mania following initiation of a ketogenic diet: case series
The ketogenic diet is a century-old, evidence-based treatment for drug-refractory epilepsy, and is now also utilized as an evidence-based treatment for obesity and type 2 diabetes. Emerging research suggests that it may play a role in the treatment of serious mental illness, including treatment-resistant depression, bipolar disorder, and schizophrenia. As with any powerful therapeutic intervention, there can sometimes be side effects. This case series of 9 participants describes 8 who experienced hypomania and 1 who experienced mania within 2 months of starting a ketogenic diet. Of note, 7 of the participants did not have a prior history of a bipolar-spectrum disorder. None of the participants required hospitalization or the addition of mood-stabilizing medications as a result of these mood episodes. Nonetheless, individuals and clinicians should be aware of this risk when using the ketogenic diet, monitor for symptoms of hypomania and mania, and use appropriate strategies to manage symptoms if they emerge. These findings also raise intriguing questions and offer possible insights into the phenomenology of hypomania and mania.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 16761-16771
The Ketogenic Diet: An Anti-Inflammatory Treatment for Schizophrenia?
Schizophrenia, a complex psychiatric disorder, is increasingly understood to involve immune dysregulation intertwined with metabolic and mitochondrial dysfunction. Neuroinflammation, driven by microglial activation, aberrant cytokine signalling, and skewed T cell polarization, intersects with impaired cellular bioenergetics and oxidative stress. Metabolic and mitochondrial alterations, consistently observed in patients, may constitute both cause and consequence of immune imbalance, sustaining a pathological loop that links bioenergetic failure to neuroinflammation. The ketogenic diet (KD), a high-fat, very low-carbohydrate intervention has recently gained attention as a potential therapy for schizophrenia. Emerging clinical reports describe improvements in symptom burden, weight regulation, and sustained remission. However, this evidence remains preliminary and is limited to pilot studies and case series. Preclinical studies provide mechanistic evidence, demonstrating that KD and its primary ketone body, β-hydroxybutyrate, attenuate core pathological features including inflammation, synaptic pruning, mitochondrial dysfunction, T cell imbalances and epigenetic alterations. Mechanistically, KD reshapes immune balance by favoring regulatory T cell induction over T helper 17 cell polarization and dampening pro-inflammatory signalling. Further to this, it improves mitochondrial biogenesis, increases ATP yield and reduces reactive oxygens species through increased efficiency of ATP hydrolysis. Epigenetic regulation by multiple pathways provides an additional layer of transcriptional control that may sustain therapeutic benefits. By framing KD within the context of inflammation research, this review synthesises findings from clinical, preclinical and mechanistic studies to highlight its potential to address fundamental disease mechanisms.
- 1 December 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 16761-16771
Open AccessThe Ketogenic Diet: An Anti-Inflammatory Treatment for Schizophrenia?
Schizophrenia, a complex psychiatric disorder, is increasingly understood to involve immune dysregulation intertwined with metabolic and mitochondrial dysfunction. Neuroinflammation, driven by microglial activation, aberrant cytokine signalling, and skewed T cell polarization, intersects with impaired cellular bioenergetics and oxidative stress. Metabolic and mitochondrial alterations, consistently observed in patients, may constitute both cause and consequence of immune imbalance, sustaining a pathological loop that links bioenergetic failure to neuroinflammation. The ketogenic diet (KD), a high-fat, very low-carbohydrate intervention has recently gained attention as a potential therapy for schizophrenia. Emerging clinical reports describe improvements in symptom burden, weight regulation, and sustained remission. However, this evidence remains preliminary and is limited to pilot studies and case series. Preclinical studies provide mechanistic evidence, demonstrating that KD and its primary ketone body, β-hydroxybutyrate, attenuate core pathological features including inflammation, synaptic pruning, mitochondrial dysfunction, T cell imbalances and epigenetic alterations. Mechanistically, KD reshapes immune balance by favoring regulatory T cell induction over T helper 17 cell polarization and dampening pro-inflammatory signalling. Further to this, it improves mitochondrial biogenesis, increases ATP yield and reduces reactive oxygens species through increased efficiency of ATP hydrolysis. Epigenetic regulation by multiple pathways provides an additional layer of transcriptional control that may sustain therapeutic benefits. By framing KD within the context of inflammation research, this review synthesises findings from clinical, preclinical and mechanistic studies to highlight its potential to address fundamental disease mechanisms.
- Open Access
- 9 May 2025
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 11 (3) , e94
The ketogenic diet and metabolic treatments for neuropsychiatric disorders
The ketogenic diet, initially developed for epilepsy treatment, has gained attention as a potential intervention for neuropsychiatric disorders. A groundbreaking study by Campbell et al highlights its feasibility and potential efficacy in bipolar disorder, shedding light on shared mechanisms across neuropsychiatric disorders and the promise of metabolic treatment approaches.
- 9 May 2025
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 11 (3) , e94
Open AccessThe ketogenic diet and metabolic treatments for neuropsychiatric disorders
The ketogenic diet, initially developed for epilepsy treatment, has gained attention as a potential intervention for neuropsychiatric disorders. A groundbreaking study by Campbell et al highlights its feasibility and potential efficacy in bipolar disorder, shedding light on shared mechanisms across neuropsychiatric disorders and the promise of metabolic treatment approaches.
- Open Access
- 16 April 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1568076
Ketogenic diet as a therapeutic intervention for obsessive-compulsive disorder: a case series of three patients
Introduction: The ketogenic diet is being explored as a therapeutic intervention for the treatment of neuropsychiatric disorders. Emerging research suggests that these conditions share common pathophysiologies, with the ketogenic diet showing promise in addressing these. This study reports three individuals who reduced their symptoms of obsessive-compulsive disorder (OCD) after adopting a ketogenic diet.Methods: Participants were recruited through personal and professional networks among the authors. Each patient was interviewed, and evidence of their mental health history was collected. Their OCD symptoms were retrospectively assessed before and after adopting the diet using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).Results: The three participants in this case series have all achieved remission of their symptoms and are medication-free. The diet implementation reduced their average Y-BOCS scores by 21 points, corresponding to a mean decrease of 90.5%. In all cases, deviations from the ketogenic diet resulted in a return of their symptoms.Conclusion: The ketogenic diet may be an effective treatment for obsessive-compulsive disorder. Its capacity to improve the metabolic dysfunction associated with OCD may target the underlying mechanisms of the disorder. Controlled clinical trials of the ketogenic diet as a treatment for OCD are warranted.
- 16 April 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1568076
Open AccessKetogenic diet as a therapeutic intervention for obsessive-compulsive disorder: a case series of three patients
Introduction: The ketogenic diet is being explored as a therapeutic intervention for the treatment of neuropsychiatric disorders. Emerging research suggests that these conditions share common pathophysiologies, with the ketogenic diet showing promise in addressing these. This study reports three individuals who reduced their symptoms of obsessive-compulsive disorder (OCD) after adopting a ketogenic diet.Methods: Participants were recruited through personal and professional networks among the authors. Each patient was interviewed, and evidence of their mental health history was collected. Their OCD symptoms were retrospectively assessed before and after adopting the diet using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).Results: The three participants in this case series have all achieved remission of their symptoms and are medication-free. The diet implementation reduced their average Y-BOCS scores by 21 points, corresponding to a mean decrease of 90.5%. In all cases, deviations from the ketogenic diet resulted in a return of their symptoms.Conclusion: The ketogenic diet may be an effective treatment for obsessive-compulsive disorder. Its capacity to improve the metabolic dysfunction associated with OCD may target the underlying mechanisms of the disorder. Controlled clinical trials of the ketogenic diet as a treatment for OCD are warranted.
- 6 January 2025
- Published by Royal College of Psychiatrists in BJPsych Advances
- p. 1-3
Beyond comorbidities: metabolic dysfunction as a root cause of neuropsychiatric disorders
SUMMARY: Metabolic dysfunction has been long associated with severe mental illness (SMI), often viewed as a comorbidity to be managed. However, emerging evidence suggests that metabolic dysfunction, particularly at the mitochondrial level, may be a foundational element in the pathophysiology of neuropsychiatric disorders. This commentary expands on the current understanding by exploring the brain energy theory of mental illness, which posits that mitochondrial dysfunction is central to both metabolic and psychiatric conditions. The roles of insulin resistance, chronic stress and environmental factors are highlighted as shared biopsychosocial determinants that contribute to deterioration in both metabolic and mental health. The therapeutic potential of the ketogenic diet is discussed, particularly its ability to improve mitochondrial function and alleviate psychiatric symptoms. This shift in perspective, from viewing metabolic dysfunction as a secondary concern to recognising it as a root cause of SMI, has significant implications for clinical practice and research. By focusing on bioenergetic deficits and mitochondrial health, psychiatry may advance towards more effective, integrated treatment approaches that target the underlying cellular dysfunctions driving both metabolic and mental illnesses.
- 6 January 2025
- Published by Royal College of Psychiatrists in BJPsych Advances
- p. 1-3
Beyond comorbidities: metabolic dysfunction as a root cause of neuropsychiatric disorders
SUMMARY: Metabolic dysfunction has been long associated with severe mental illness (SMI), often viewed as a comorbidity to be managed. However, emerging evidence suggests that metabolic dysfunction, particularly at the mitochondrial level, may be a foundational element in the pathophysiology of neuropsychiatric disorders. This commentary expands on the current understanding by exploring the brain energy theory of mental illness, which posits that mitochondrial dysfunction is central to both metabolic and psychiatric conditions. The roles of insulin resistance, chronic stress and environmental factors are highlighted as shared biopsychosocial determinants that contribute to deterioration in both metabolic and mental health. The therapeutic potential of the ketogenic diet is discussed, particularly its ability to improve mitochondrial function and alleviate psychiatric symptoms. This shift in perspective, from viewing metabolic dysfunction as a secondary concern to recognising it as a root cause of SMI, has significant implications for clinical practice and research. By focusing on bioenergetic deficits and mitochondrial health, psychiatry may advance towards more effective, integrated treatment approaches that target the underlying cellular dysfunctions driving both metabolic and mental illnesses.
- Open Access
- 21 November 2024
- Published by Springer Nature in Current Treatment Options in Psychiatry
- Vol. 12 (1) , 1-35
The Ketogenic Diet as a Transdiagnostic Treatment for Neuropsychiatric Disorders: Mechanisms and Clinical Outcomes
- 21 November 2024
- Published by Springer Nature in Current Treatment Options in Psychiatry
- Vol. 12 (1) , 1-35
Open AccessThe Ketogenic Diet as a Transdiagnostic Treatment for Neuropsychiatric Disorders: Mechanisms and Clinical Outcomes
- Open Access
- 28 May 2024
- Published by Springer Nature in Current Treatment Options in Psychiatry
- Vol. 11 (3) , 163-176
The Ketogenic Diet as a Treatment for Mood Disorders
Purpose of Review: The ketogenic diet is a low carbohydrate, moderate protein, and high fat diet which results in a metabolic state known as ketosis, in which fats are broken down into ketone bodies. The ketogenic diet is a 100-year-old evidence-based treatment for epilepsy and is gaining popularity as a treatment for various mental disorders, including mood disorders. Our objective is to explain the potential mechanisms through which ketogenic diets may improve the pathophysiology of mood disorders and provide a comprehensive review of recent clinical literature on the topic Recent Findings: Mood disorders are associated with several proposed pathophysiological mechanisms, including mitochondrial dysfunction, oxidative stress, inflammation, and insulin resistance. The ketogenic diet shows promise in addressing these underlying pathophysiological mechanisms and emerging clinical data suggest that ketogenic diets may improve symptoms in people with mood disorders. Summary: The ketogenic diet shows promise in the treatment of mood disorders. This metabolic intervention has the potential to directly target underlying disease mechanisms, potentially reduce the need for medications, and reduce common side effects and comorbidities, such as weight gain and insulin resistance.
- 28 May 2024
- Published by Springer Nature in Current Treatment Options in Psychiatry
- Vol. 11 (3) , 163-176
Open AccessThe Ketogenic Diet as a Treatment for Mood Disorders
Purpose of Review: The ketogenic diet is a low carbohydrate, moderate protein, and high fat diet which results in a metabolic state known as ketosis, in which fats are broken down into ketone bodies. The ketogenic diet is a 100-year-old evidence-based treatment for epilepsy and is gaining popularity as a treatment for various mental disorders, including mood disorders. Our objective is to explain the potential mechanisms through which ketogenic diets may improve the pathophysiology of mood disorders and provide a comprehensive review of recent clinical literature on the topic Recent Findings: Mood disorders are associated with several proposed pathophysiological mechanisms, including mitochondrial dysfunction, oxidative stress, inflammation, and insulin resistance. The ketogenic diet shows promise in addressing these underlying pathophysiological mechanisms and emerging clinical data suggest that ketogenic diets may improve symptoms in people with mood disorders. Summary: The ketogenic diet shows promise in the treatment of mood disorders. This metabolic intervention has the potential to directly target underlying disease mechanisms, potentially reduce the need for medications, and reduce common side effects and comorbidities, such as weight gain and insulin resistance.
- 16 December 2021
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 50 (1) , 102
235: PATIENT MEMORIES FROM THE INTENSIVE CARE UNIT FOLLOWING COVID-19
- 16 December 2021
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 50 (1) , 102
235: PATIENT MEMORIES FROM THE INTENSIVE CARE UNIT FOLLOWING COVID-19